OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Goetz on the Impact of the PALOMA-2 Trial in ER+/HER2- Breast Cancer

December 1st 2022

Matthew P. Goetz, MD, discusses the impact of the phase 3 PALOMA-2 trial in estrogen receptor–positive/HER2-negative advanced breast cancer.

Dr. Schmid on Next Steps for the RACE IT Trial in Urothelial Carcinoma

December 1st 2022

Sebastian C. Schmid, MD, discusses the future of the phase 2 RACE IT trial in urothelial carcinoma.

Dr. Pavlick on Sequencing Immunotherapy Vs Targeted Therapy in BRAF-Mutated Melanoma

December 1st 2022

Anna C. Pavlick, DO, discusses the sequencing of immunotherapy vs targeted therapy in BRAF-mutated melanoma.

Dr. Conlin on the Implications of the HER2-Low Subset in Breast Cancer

November 30th 2022

Alison K. Conlin, MD, discusses the inception of the HER2-low breast cancer treatment landscape.

Dr. Klempner on the Investigation of Adagrasib in KRAS G12C–Mutated mCRC

November 30th 2022

Sam Klempner, MD, discusses the investigation of adagrasib in KRAS G12C–mutated metastatic colorectal cancer.

Dr. Susanibar-Adaniya on the Standard of Care for Patients With Newly Diagnosed Multiple Myeloma

November 30th 2022

Sandra P. Susanibar-Adaniya, MD, discusses the current standard of care for patients with newly diagnosed multiple myeloma.

Experts on the Management of Diarrhea Associated With EGFR TKIs

November 29th 2022

Zosia Piotrowska, MD, Jonathan Riess, MD, MS, Gregory Riely, MD, Emily Skotte, MSN, APRN, ACNP-BC, and Amanda Cass, PharmD, BCPS, discuss the management of diarrhea as an adverse effect associated with EGFR TKIs.

Experts Discuss the Management of Paronychia When Treating Patients with EGFR TKIs

November 29th 2022

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the management of paronychia when treating patients with EGFR TKIs.

Experts Discuss How to Address Cardiac-Related Toxicities With EGFR TKIs

November 29th 2022

Gregory Riely, MD, and Shirish Gadgeel, MD, discuss how to address cardiac-related toxicities associated with treatment with EGFR TKIs.

Experts Discuss the Safety Profile of Mobocertinib in EGFR Exon 20–Mutated Advanced NSCLC

November 29th 2022

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP, discuss the safety profile of mobocertinib in EGFR exon 20 insertion mutation–positive advanced non–small cell lung cancer.

Dr. Brody on Updated Data From the ECHELON-1 Trial in Hodgkin Lymphoma

November 29th 2022

Joshua Brody, MD, discusses key follow-up data from the phase 3 ECHELON-1 trial in classical Hodgkin lymphoma.

Dr. Liu on the Development of Frontline Atezolizumab Combination Therapies in SCLC

November 29th 2022

Stephen V. Liu, MD, discusses efforts to develop atezolizumab-based combination therapies for patients with small cell lung cancer.

Experts Discuss Common AEs With EGFR TKIs

November 29th 2022

Zosia Piotrowska, MD, Christine Lovly, MD, PhD, and Amanda Cass, PharmD, BCPS, BCOP discuss common adverse effects with EGFR TKIs.

Experts Discuss the Risk of Skin Toxicities Associated With EGFR TKIs

November 29th 2022

Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, Jonathan Riess, MD, MS, and Ticiana Leal, MD, discuss the impact of skin toxicities when utilizing EGFR TKIs.

Experts Discuss Management of Skin and Mouth TRAEs Associated With EGFR TKIs

November 28th 2022

Christine Lovly, MD, PhD, Jeanne G. Vaughn, NP, Kristina Lo, PharmD, BCOP, and Linda Ahn discuss how to approach treatment-related adverse effects of the skin and mouth associated with the use of EGFR TKIs.

Dr. Shah on Unmet Needs With CAR T-Cell Therapies in Hematologic Malignancies

November 28th 2022

Nirav N. Shah, MD, discusses remaining unmet needs with CAR T-cell therapies, and how to ameliorate these challenges for patients with hematologic malignancies.

Dr. Mascarenhas on Advancements in the Treatment Landscape of Myelofibrosis

November 28th 2022

John O. Mascarenhas, MD, discusses current advancement in the treatment landscape of myelofibrosis.

Dr. Hamilton on Trastuzumab Deruxtecan in HER2+ Breast Cancer

November 28th 2022

Erika P. Hamilton, MD, discusses previously reported and anticipated findings from the DESTINY-Breast03 trial, which compared the efficacy of 2 antibody-drug conjugates, fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine, in patients with HER2-positive metastatic breast cancer.

Dr. Moskowitz on Antibody-Drug Conjugates in Relapsed/Refractory DLBCL

November 28th 2022

Craig Moskowitz, MD, discusses the efficacy of several antibody-drug conjugates in diffuse large B-cell lymphoma, how their adverse effect profiles compare, and how bispecific antibodies are further defining the DLBCL treatment landscape.

Dr. Jabbour on MRD Testing in B-ALL

November 23rd 2022

Elias Jabbour, MD, discusses the importance of testing for minimal residual disease when determining optimal treatment strategies for patients with B-cell acute lymphoblastic leukemia.